Early Neuroprognostication After OHCA

Launched by LUND UNIVERSITY · Jan 20, 2023

Keywords

ClinConnect Summary

This clinical trial, called "Early Neuroprognostication After OHCA," is looking to find out if doctors can predict how well a person’s brain will recover after a cardiac arrest sooner than the current standard of 72 hours. The study is part of a larger trial and focuses on patients who have had a cardiac arrest outside of the hospital due to non-traumatic reasons. To be eligible, participants must be adults aged 18 or older, have experienced at least 20 minutes without chest compressions, and be unconscious or sedated. They need to be admitted to the hospital within 4 hours after their heart has started beating again.

If someone joins this trial, they can expect to undergo various tests, such as brain scans and assessments, to help doctors understand their neurological condition more quickly. The goal is to improve how we predict recovery and ultimately provide better care for patients after a cardiac arrest. This trial is currently recruiting participants, and it is important to note that certain individuals, like those on specific heart-lung support machines or with certain medical conditions, may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Adult cardiac arrest patients with an out-of-hospital cardiac arrest of non-traumatic cause treated at hospitals recruiting patients to the STEPCARE neuroprognostication substudy. Other inclusion criteria include:
• • a minimum of 20 minutes without chest compressions
• • Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of \<4) or being intubated and sedated because of agitation after sustained ROSC
• • Eligible for intensive care without restrictions or limitations
• • Inclusion within 4 hours of ROSC
• Exclusion Criteria:
• • On ECMO prior to randomisation
• • Pregnancy
• • Suspected or confirmed intracranial hemorrhage
• • Previously randomised in the STEPCARE trial
• • Patients with limitations in level-of-care due to for example generalized malignancy